1463459-96-2
1463459-96-2 structure
- Name: Ascrinvacumab
- Chemical Name: Ascrinvacumab
- CAS Number: 1463459-96-2
- Molecular Formula:
- Molecular Weight:
- Catalog: Signaling Pathways Protein Tyrosine Kinase/RTK ALK
- Create Date: 2023-01-14 19:11:00
- Modify Date: 2024-09-17 12:00:40
-
Ascrinvacumab (PF-03446962) is a human IgG2 monoclonal antibody targets ALK-1. Ascrinvacumab shows binding efficiency with human ALK1 with a Kd value of 7 nM. Ascrinvacumab can be used for the research of hepatocellular carcinoma (HCC)[1].
| Name | Ascrinvacumab |
|---|
| Description | Ascrinvacumab (PF-03446962) is a human IgG2 monoclonal antibody targets ALK-1. Ascrinvacumab shows binding efficiency with human ALK1 with a Kd value of 7 nM. Ascrinvacumab can be used for the research of hepatocellular carcinoma (HCC)[1]. |
|---|---|
| Related Catalog | |
| In Vitro | Ascrinvacumab 与细胞人 ALK1 结合，Kd 值为 7 nm[1]。 Ascrinvacumab (30 分钟) 阻断 BMP9 和 FCS 诱导的应答，缓解 BMP9 诱导的 Smad1 磷酸化强度和持续时间[1]。 Ascrinvacumab (0.01-10 μg/mL; 2 h) 抑制 BMP9 结合到 ALK1[1]。 Ascrinvacumab (40 μg/mL; 2 h) 有效抑制人脐静脉内皮细胞 (HUVECs) 的内皮萌发[1]。 |
| In Vivo | Ascrinvacumab 联合贝伐单抗 (bevacizumab; anti-VEGF) 可降低人血管密度，提高抗肿瘤疗效在小鼠嵌合体肿瘤模型中[1]。 |
| References |
| No Any Chemical & Physical Properties |